C-reactive protein and ovarian cancer: A prospective study nested in three cohorts (Sweden, USA, Italy)

Cancer Causes and Control

Volumn 20, Issue 7, 2009, Pages 1151-1159

  Lundin, Eva ^a   Dossus, Laure ^b   Clendenen, Tess ^c   Krogh, Vittorio ^d   Grankvist, Kjell ^a   Wulff, Marianne ^a   Sieri, Sabina ^d   Arslan, Alan A ^c   Lenner, Per ^a   Berrino, Franco ^d   Hallmans, Goran ^a   Zeleniuch Jacquotte, Anne ^c   Toniolo, Paolo ^c   Lukanova, Annekatrin ^b  

^a UMEÅ UNIVERSITY   (Sweden)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

C reactive protein; Inflammation; Ovarian cancer; Prospective study

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CHRONIC INFLAMMATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SWEDEN; UNITED STATES;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; ITALY; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; UNITED STATES;

EID: 68449088876     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-009-9330-2     Document Type: Article

References (42)

1. RB Ness C Cottreau 1999 Possible role of ovarian epithelial inflammation in ovarian cancer J Natl Cancer Inst 91 1459 1467 10.1093/jnci/91.17.1459
2. LL Espey 1994 Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction Biol Reprod 50 233 238 10.1095/biolreprod50.2.233
3. JS Fleming CR Beaugie I Haviv G Chenevix-Trench OL Tan 2006 Incessant ovulation, inflammation and epithelial ovarian carcinogenesis: revisiting old hypotheses Mol Cell Endocrinol 247 4 21 10.1016/j.mce.2005.09.014 (Pubitemid 43277703)
4. HA Risch GR Howe 1995 Pelvic inflammatory disease and the risk of epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 4 447 451
5. LA Brinton G Gridley I Persson J Baron A Bergqvist 1997 Cancer risk after a hospital discharge diagnosis of endometriosis Am J Obstet Gynecol 176 572 579 10.1016/S0002-9378(97)70550-7 (Pubitemid 27147164)
6. JM Schildkraut PJ Schwingl E Bastos A Evanoff C Hughes 1996 Epithelial ovarian cancer risk among women with polycystic ovary syndrome Obstet Gynecol 88 554 559 10.1016/0029-7844(96)00226-8 (Pubitemid 26326017)
7. BL Harlow PA Hartge 1995 A review of perineal talc exposure and risk of ovarian cancer Regul Toxicol Pharmacol 21 254 260 10.1006/rtph.1995.1039
8. SE Hankinson DJ Hunter GA Colditz 1993 Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study JAMA 270 2813 2818 10.1001/jama.270.23.2813 (Pubitemid 23361643)
9. A Loft O Lidegaard A Tabor 1997 Incidence of ovarian cancer after hysterectomy: a nationwide controlled follow up Br J Obstet Gynaecol 104 1296 1301
10. A Green D Purdie C Bain 1997 Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group Int J Cancer 71 948 951 10.1002/(SICI)1097-0215(19970611)71:6<948::AID-IJC6>3.0. CO;2-Y (Pubitemid 27252873)
11. DW Cramer BL Harlow L Titus-Ernstoff K Bohlke WR Welch ER Greenberg 1998 Over-the-counter analgesics and risk of ovarian cancer Lancet 351 104 107 10.1016/S0140-6736(97)08064-1 (Pubitemid 28026637)
12. L Rosenberg JR Palmer RS Rao 2000 A case-control study of analgesic use and ovarian cancer Cancer Epidemiol Biomarkers Prev 9 933 937
13. JM Schildkraut PG Moorman S Halabi B Calingaert JR Marks A Berchuck 2006 Analgesic drug use and risk of ovarian cancer Epidemiology 17 104 107 10.1097/01.ede.0000190538.55645.f8 (Pubitemid 43755787)
14. M Karin FR Greten 2005 NF-kappaB: linking inflammation and immunity to cancer development and progression Nat Rev Immunol 5 749 759 10.1038/nri1703 (Pubitemid 41400849)
15. JK Kundu YJ Surh 2008 Inflammation: gearing the journey to cancer Mutat Res 659 15 30 10.1016/j.mrrev.2008.03.002
16. C Gabay I Kushner 1999 Acute-phase proteins and other systemic responses to inflammation N Engl J Med 340 448 454 10.1056/NEJM199902113400607 (Pubitemid 29084777)
17. C Siemes LE Visser JW Coebergh 2006 C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study J Clin Oncol 24 5216 5222 10.1200/JCO.2006.07.1381 (Pubitemid 46631365)
18. D Il'yasova LH Colbert TB Harris 2005 Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort Cancer Epidemiol Biomarkers Prev 14 2413 2418 10.1158/1055-9965.EPI-05-0316 (Pubitemid 41437845)
19. D Trichopoulos T Psaltopoulou P Orfanos A Trichopoulou P Boffetta 2006 Plasma C-reactive protein and risk of cancer: a prospective study from Greece Cancer Epidemiol Biomarkers Prev 15 381 384 10.1158/1055-9965.EPI-05-0626 (Pubitemid 43348407)
20. MA McSorley AJ Alberg DS Allen 2007 C-reactive protein concentrations and subsequent ovarian cancer risk Obstet Gynecol 109 933 941
21. G Hallmans A Agren G Johansson 2003 Cardiovascular disease and diabetes in the Northern Sweden Health and Disease Study Cohort-evaluation of risk factors and their interactions Scand J Public Health Suppl 61 18 24 10.1080/14034950310001432
22. P Toniolo PF Bruning A Akhmedkhanov 2000 Serum insulin-like growth factor-I and breast cancer Int J Cancer 88 828 832 10.1002/1097-0215(20001201) 88:5<828::AID-IJC22>3.0.CO;2-8 (Pubitemid 30819152)
23. P Muti HL Bradlow A Micheli 2000 Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women Epidemiology 11 635 640 10.1097/00001648-200011000-00004 (Pubitemid 30796720)
24. A Lukanova E Lundin A Akhmedkhanov 2003 Circulating levels of sex steroid hormones and risk of ovarian cancer Int J Cancer 104 636 642 10.1002/ijc.10990 (Pubitemid 36337265)
25. SAS Institute (1990) SAS/STATR user's guide version 6. SAS Institute Inc. Cary, NC, USA
26. WG Cochran 1954 The combination of estimates from different experiments Biometrics 10 101 129 10.2307/3001666
27. JP Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analyses BMJ 327 557 560 10.1136/bmj.327.7414.557
28. VW Chen B Ruiz JL Killeen TR Cote XC Wu CN Correa 2003 Pathology and classification of ovarian tumors Cancer 97 2631 2642 10.1002/cncr.11345
29. Seidman JD, Russell P, Kurman RJ (2002) Surface epithelial tumors of the ovary. In: Kurman RJ (ed) Blaustein's pathology of the female genital tract. Springer-Verlag, New York, pp 791-904
30. N Rifai PM Ridker 2003 Population distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretation Clin Chem 49 666 669 10.1373/49.4.666 (Pubitemid 36379538)
31. A Imhof M Frohlich H Loewel 2003 Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe Clin Chem 49 669 672 10.1373/49.4.669 (Pubitemid 36379539)
32. TA Pearson GA Mensah RW Alexander 2003 Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 499 511 10.1161/01.CIR.0000052939.59093.45 (Pubitemid 36158056)
33. SM Zhang J Lin NR Cook 2007 C-reactive protein and risk of breast cancer J Natl Cancer Inst 99 890 894 10.1093/jnci/djk202 (Pubitemid 47073511)
34. A Talbot-Smith L Fritschi ML Divitini DF Mallon MW Knuiman 2003 Allergy, atopy, and cancer: a prospective study of the 1981 Busselton cohort Am J Epidemiol 157 606 612 10.1093/aje/kwg020 (Pubitemid 36368531)
35. M Kobel SE Kalloger N Boyd 2008 Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 e232 10.1371/journal.pmed.0050232
36. RJ Kurman I Shih 2008 Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications Int J Gynecol Pathol 27 151 160
37. ML Gemignani AC Schlaerth F Bogomolniy 2003 Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma Gynecol Oncol 90 378 381 10.1016/S0090-8258(03)00264-6 (Pubitemid 36952030)
38. IA Lea MA Jackson X Li S Bailey SD Peddada JK Dunnick 2007 Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns Carcinogenesis 28 1851 1858 10.1093/carcin/bgm176 (Pubitemid 47504878)
39. TP Erlinger EA Platz N Rifai KJ Helzlsouer 2004 C-reactive protein and the risk of incident colorectal cancer JAMA 291 585 590 10.1001/jama.291.5.585 (Pubitemid 38500312)
40. K Tsilidis C Branchini E Guallar KJ Helzlsouer TP Erlinger EA Platz 2008 C-reactive protein and colorectal cancer risk: a systemic review of prospective studies Int J Cancer 123 1133 1140 10.1002/ijc.23606
41. J Kodama Y Miyagi N Seki 1999 Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer Eur J Obstet Gynecol Reprod Biol 82 107 110 10.1016/S0301-2115(98)00227-9 (Pubitemid 29042226)
42. LA Hefler N Concin G Hofstetter 2008 Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer Clin Cancer Res 14 710 714 10.1158/1078-0432.CCR-07-1044 (Pubitemid 351231151)